NSQHS Standard 7: Blood Management for Australian Healthcare Facilities

Blood is one of Australia's most precious healthcare resources. Every unit of red cells, plasma, or platelets exists because a volunteer donor gave their time and a piece of themselves. The National Blood Authority (NBA) manages a supply that costs the Australian Government over $1.6 billion annually. When a blood product reaches your facility, it carries an obligation: use it wisely, use it safely, and account for every unit.

NSQHS Standard 7 exists to make sure that happens. It covers the entire lifecycle of blood and blood products in your organisation, from the decision to prescribe through to monitoring the patient after transfusion. If your facility handles blood products at all, this standard applies to you.

Getting it wrong has real consequences. Transfusion errors can cause haemolytic reactions, transfusion-related acute lung injury (TRALI), or bacterial sepsis. Getting it right means patients receive the right product, at the right time, with proper consent and monitoring. It also means fewer wasted units in a system that can't afford waste.

If you're working through all eight NSQHS Standards, our complete NSQHS standards guide gives you the big picture before you drill into individual standards.

What does NSQHS Standard 7 require?

Standard 7 of the National Safety and Quality Health Service Standards is titled "Blood Management." It applies to all health service organisations assessed against the NSQHS Standards that prescribe, dispense, or administer blood and blood products.

The standard has four core action areas:

Clinical governance and quality improvement to support blood management
Prescribing and clinical use of blood and blood products
Managing the availability and safety of blood and blood products
Communicating with patients about blood management, including informed consent

Each action area contains specific actions your organisation must demonstrate compliance against. The standard aligns closely with the NBA's Patient Blood Management Guidelines, so if you're already following those, you have a strong foundation.

For nurses working at the bedside, our NSQHS nursing guide breaks down how each standard translates into day-to-day clinical practice.

Who is responsible for blood management governance?

Governance is the backbone of Standard 7. Your organisation needs a defined structure for overseeing blood management, and it needs to be more than a name on an org chart.

At minimum, you need:

A blood management committee or lead with documented terms of reference and authority to drive improvement
Policies and procedures covering the full blood product lifecycle: prescribing, ordering, collection, storage, transport, administration, and disposal
A risk management framework that identifies blood-specific risks (wrong blood, cold chain failure, delayed transfusion, consent gaps)
Incident reporting and review processes for transfusion-related adverse events
Regular data collection and audit to monitor compliance and guide improvement

In larger hospitals, a dedicated Transfusion Committee typically handles this. In smaller facilities, blood management may sit under your broader clinical governance structure. Either way, the functions must be covered.

| Governance Element | Large Hospital | Smaller Facility | |---|---|---| | Oversight body | Dedicated Transfusion Committee | Standing item at clinical governance meeting | | Blood management lead | Transfusion nurse/haematologist | Nominated clinician with blood management training | | Policy suite | Comprehensive, procedure-specific | Consolidated but covering all action areas | | Audit program | Formal with dedicated audit staff | Integrated into existing audit cycles | | Incident review | Transfusion Committee review | Clinical governance meeting agenda item |

The key question auditors ask: is your governance active and effective, or is it paperwork that nobody reads? Evidence of meeting minutes, action items, completed audits, and closed-loop incident reviews demonstrates the former.

What is a patient blood management program?

Patient blood management (PBM) is a systematic, evidence-based approach to optimising the care of patients who might need a transfusion. The goal is straightforward: improve patient outcomes by minimising unnecessary transfusion while ensuring blood is available when genuinely needed.

The NBA's Patient Blood Management Guidelines provide the clinical framework. PBM rests on three pillars:

Optimise the patient's own blood before surgery or procedures (e.g., treat iron deficiency anaemia preoperatively)
Minimise blood loss during procedures through surgical technique, pharmacological agents, and cell salvage where appropriate
Optimise the patient's tolerance of anaemia by managing oxygen delivery and reducing oxygen consumption

Under Standard 7, your organisation must demonstrate that PBM principles are embedded in clinical practice. That means:

Preoperative assessment includes haemoglobin screening and iron studies where relevant
Anaemia is identified and managed before elective procedures
Transfusion triggers are based on clinical guidelines, not arbitrary haemoglobin thresholds
Single-unit transfusion is the default for stable, non-bleeding patients (with reassessment after each unit)
Blood product use is regularly audited against PBM guidelines

The single-unit policy is worth emphasising. For decades, the default was to transfuse two units of red cells. Evidence now shows that for haemodynamically stable patients, transfusing one unit and reassessing is safer and reduces unnecessary exposure. If your facility still defaults to two-unit orders, that's a gap auditors will notice.

How should blood products be prescribed and used?

Prescribing blood products carries the same responsibilities as prescribing any medication, with some additional requirements unique to the risks involved.

Standard 7 requires that:

Blood products are prescribed by authorised clinicians in accordance with current evidence-based guidelines
The clinical indication for transfusion is documented in the patient's medical record
Pre-transfusion laboratory testing (group and screen or crossmatch) is ordered and results reviewed before administration
The prescriber considers alternatives to transfusion where appropriate

The documentation requirement matters more than you might think. "Low Hb" is not an adequate clinical indication. Auditors expect to see the specific clinical reasoning: active bleeding with haemodynamic compromise, symptomatic anaemia unresponsive to iron therapy, preoperative optimisation, or similar. This documentation also supports your PBM program by allowing you to audit appropriateness of transfusion decisions.

| Blood Product | Common Indications | Key Prescribing Considerations | |---|---|---| | Red blood cells | Acute haemorrhage, symptomatic anaemia | Single-unit default; reassess after each unit | | Fresh frozen plasma (FFP) | Coagulopathy with bleeding, massive transfusion | Not for volume replacement alone | | Platelets | Thrombocytopenia with bleeding or pre-procedure | Check for contraindications (e.g., TTP/HIT) | | Cryoprecipitate | Fibrinogen deficiency, DIC | Often part of massive transfusion protocol | | Albumin | Specific clinical indications only | Not for general nutritional support |

What does informed consent for transfusion look like?

Informed consent for blood transfusion is a specific requirement under Standard 7, and it regularly shows up as a finding in accreditation assessments.

Consent must be obtained before transfusion except in life-threatening emergencies. The consent process requires that the patient (or their substitute decision-maker) is informed about:

Why the transfusion is recommended
What product will be given
Benefits and risks, including common and serious adverse reactions
Alternatives to transfusion, including the option to decline
What happens if they choose not to receive blood products

Consent should be documented. Most facilities use a specific blood transfusion consent form, but the format matters less than the content and the quality of the conversation.

For patients who refuse blood products on religious or personal grounds (most commonly Jehovah's Witnesses), your facility needs a documented process. This includes an advance care directive or specific refusal form, a management plan that outlines alternatives, and clear communication across the treating team.

Common consent pitfalls:

Consent obtained by a junior clinician who can't adequately explain risks and alternatives
Generic consent forms that don't mention blood transfusion specifically
Consent obtained after the transfusion has already started
No documentation of the consent conversation in the medical record
No process for managing patients who decline blood products

How do you maintain the cold chain for blood products?

Cold chain management is where Standard 7 intersects with logistics, and a single failure can render a blood product unsafe. Blood products are temperature-sensitive biological materials. Break the cold chain, and you risk bacterial contamination or loss of product efficacy.

Your organisation must have documented procedures for:

Storage: Blood fridges must maintain 2 to 6 degrees Celsius with continuous temperature monitoring and alarms. Platelet incubators operate at 20 to 24 degrees with agitation. FFP and cryo require minus 25 degrees or below.
Transport: Blood products must be transported in validated containers that maintain the required temperature range. Transport time limits must be defined and monitored.
Issue and return: Clear timeframes for when a product can be returned to inventory after issue (generally within 30 minutes if the cold chain has been maintained).
Equipment maintenance: Blood fridges, platelet incubators, and freezers must be regularly serviced and calibrated, with documented maintenance logs.
Alarm response: A documented escalation process for temperature excursions, including who to contact and what decisions need to be made about affected stock.

| Product | Storage Temperature | Critical Notes | |---|---|---| | Red blood cells | 2 to 6°C | Must begin transfusion within 30 minutes of removal from fridge | | Platelets | 20 to 24°C with agitation | Short shelf life (5 days); do not refrigerate | | Fresh frozen plasma | ≤ -25°C (stored); thaw before use | Once thawed, use within 24 hours | | Cryoprecipitate | ≤ -25°C (stored); thaw before use | Once thawed, use within 4 to 6 hours |

Temperature excursions are a common audit finding. If your blood fridge alarm goes off at 2am and nobody responds for three hours, that's a reportable cold chain breach. Your process needs to define maximum response times and ensure after-hours coverage.

What are the pre-transfusion check requirements?

The pre-transfusion check is the last line of defence against a wrong-blood-in-tube or wrong-blood-to-patient error. These errors are rare, but when they occur the consequences can be fatal. ABO-incompatible transfusion remains one of the most serious preventable adverse events in healthcare.

Standard 7 requires a robust patient identification and product verification process at the point of administration. The standard approach in Australia involves:

At blood sample collection:

Positive patient identification at the bedside (ask the patient to state their full name and date of birth; check against their identification band)
Label the sample tubes at the bedside immediately after collection (never pre-label tubes)
The person who collected the sample signs the request form

At the bedside before transfusion:

Two clinicians independently verify patient identity, product details, and compatibility
Check the patient's full name, date of birth, and medical record number against the blood product label and the compatibility report
Verify the product type, unit number, expiry date, and blood group
Confirm the prescription matches the product being administered
Check for any special requirements (e.g., irradiated, CMV-negative)

This is a non-negotiable two-person check. Shortcuts here kill patients. If your facility has workarounds because "the second nurse is busy" or "it's after hours and there's only one nurse," you have a system problem that needs solving before an accreditation assessment finds it.

Electronic blood management systems can add an additional safety layer, but they supplement rather than replace the bedside check.

How should you monitor for transfusion reactions?

Transfusion reactions range from mild (febrile non-haemolytic reactions, minor allergic reactions) to life-threatening (acute haemolytic reactions, anaphylaxis, TRALI, transfusion-associated circulatory overload). Your monitoring protocol must be designed to detect all of these.

Standard 7 requires:

Baseline observations (temperature, pulse, blood pressure, respiratory rate) before starting the transfusion
Observations at 15 minutes after the transfusion begins (this is when acute haemolytic reactions typically present)
Regular observations during the transfusion (frequency varies by facility policy, but at least hourly is standard)
Post-transfusion observations on completion
A documented process for recognising and managing transfusion reactions, including when to stop the transfusion, what investigations to order, and who to notify

Staff administering blood products must be trained to recognise the signs and symptoms of transfusion reactions. A quick-reference chart at the bedside or on your intranet is good practice.

| Reaction Type | Onset | Key Signs | Immediate Action | |---|---|---|---| | Acute haemolytic | Minutes | Fever, rigors, flank pain, dark urine, hypotension | Stop transfusion; IV fluids; notify medical officer and blood bank | | Febrile non-haemolytic | During or shortly after | Temperature rise ≥1°C, chills | Slow or stop transfusion; assess clinically | | Allergic (mild) | During transfusion | Urticaria, itch, localised rash | Slow transfusion; administer antihistamine | | Anaphylaxis | Minutes | Hypotension, bronchospasm, angioedema | Stop transfusion; adrenaline; emergency response | | TRALI | Within 6 hours | Acute dyspnoea, hypoxia, bilateral infiltrates on CXR | Stop transfusion; supportive care; notify blood bank | | TACO | During or within 6 hours | Dyspnoea, hypertension, pulmonary oedema | Stop or slow transfusion; diuretics; sit patient upright |

All transfusion reactions must be reported through your incident management system. Serious reactions must also be reported to the blood bank and, depending on severity, to the NBA's haemovigilance program.

What should a massive transfusion protocol include?

A massive transfusion protocol (MTP) is a predefined, coordinated response for patients requiring large volumes of blood products in a short timeframe. Think major trauma, obstetric haemorrhage, or GI bleeding with haemodynamic collapse.

Not every facility needs a full MTP. If your organisation doesn't manage patients who might require massive transfusion (e.g., a standalone allied health clinic), this action area may be assessed as not applicable. But if you're a hospital, day surgery centre with procedural risk, or maternity service, you need one.

Your MTP should define:

Activation criteria (who can activate, what clinical triggers apply)
A predefined product ratio (e.g., red cells to FFP to platelets), consistent with NBA guidelines
Communication pathways between the clinical team, blood bank, and laboratory
Roles and responsibilities during activation
Monitoring requirements including point-of-care testing (blood gas, fibrinogen levels, viscoelastic testing if available)
Deactivation criteria and post-event debrief process

Regular simulation exercises (at least annually) test whether your MTP actually works under pressure. Paper protocols are useless if your team hasn't practised the workflow. Debrief after every real activation and every simulation to identify and fix gaps.

What do auditors look for in a Standard 7 assessment?

Auditors assess Standard 7 by looking at your systems, your documentation, and your practice. They will review policies, observe clinical practice, interview staff, and examine patient records.

Here is what commonly triggers findings:

Consent gaps: No blood-specific consent form, consent obtained after transfusion started, or no documented process for patients who refuse blood
Cold chain breaches: Temperature excursion logs without evidence of investigation or corrective action
Pre-transfusion check shortcuts: Facilities where the two-person check is inconsistently performed or not documented
Missing clinical indications: Transfusion orders without documented clinical reasoning
No PBM program: Facilities that transfuse routinely without evidence of considering alternatives or optimising the patient's own blood first
Audit gaps: No regular audit of blood product usage, wastage, or transfusion practice
Staff knowledge: Clinical staff who cannot describe the signs of a transfusion reaction or explain the pre-transfusion check process
MTP not tested: A massive transfusion protocol that has never been simulated or debriefed

The strongest facilities treat Standard 7 as a continuous improvement cycle, not a pre-accreditation scramble. Regular audits, active governance, staff education, and real-time monitoring of transfusion practice all contribute to sustained compliance.

If you're finding it difficult to keep track of policies, audit schedules, and staff training across multiple NSQHS Standards, AHCRA's compliance platform brings everything into one system. You can manage your blood management policies alongside infection control, clinical governance, and every other compliance requirement without spreadsheets or shared drives.

Frequently asked questions

Does Standard 7 apply to facilities that don't store blood products on site?

Yes, if your facility prescribes or administers blood products, Standard 7 applies. Even if products are sourced from an external blood bank and delivered for specific patients, you're still responsible for the cold chain from receipt, administration, monitoring, and consent. The scope may be narrower, but the obligations still exist.

How often should blood management audits be conducted?

The standard doesn't prescribe a specific frequency, but best practice is at least annually for comprehensive audits of transfusion appropriateness, consent compliance, and cold chain management. More frequent targeted audits (e.g., quarterly pre-transfusion check compliance) help you catch problems early. Your audit schedule should be documented in your blood management governance plan.

What training do staff need for blood product administration?

All clinical staff involved in blood product administration must be trained and assessed as competent. Training should cover patient identification, the pre-transfusion bedside check, safe administration, monitoring for reactions, and emergency response. Most facilities require annual competency reassessment. AHCRA's compliance training courses include modules aligned to NSQHS requirements, including blood management.

Can electronic blood management systems replace manual checks?

Electronic systems (such as barcode scanning for patient identification and product verification) add a valuable safety layer and can reduce wrong-blood errors. However, they do not replace the requirement for clinical assessment and two-person verification at the bedside. Think of electronic systems as an additional check, not a substitute. If your electronic system fails, your staff need to be competent in performing manual checks.

What happens if a patient refuses blood products?

Your facility must have a documented process for managing patients who refuse blood products. This includes an informed refusal discussion, a signed refusal or advance care directive, a management plan outlining alternative treatments, and communication to the entire treating team. The patient's decision must be respected, but the discussion and alternatives must be thoroughly documented.

Sources

Australian Commission on Safety and Quality in Health Care. NSQHS Standards: Blood Management Standard. ACSQHC, 2021.
National Blood Authority. Patient Blood Management Guidelines. NBA, Australian Government.
National Blood Authority. Australian Haemovigilance Report. NBA, Australian Government.
Australian Red Cross Lifeblood. Blood Component Information. Australian Red Cross Lifeblood.

Blood management compliance is one of those areas where the detail matters and the stakes are high. If you're preparing for accreditation or just tightening up your systems, get in touch with AHCRA to see how we can help you stay on top of Standard 7 and every other NSQHS requirement.